ScaleReady announces a G-Rex® Grant has been awarded to ImmunoScape

Rhea-AI Summary

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne (NASDAQ: TECH), and CellReady, has awarded a $250,000 G-Rex® Grant to ImmunoScape Pte. This grant will support ImmunoScape's process development and IND enabling studies for their novel WT1-targeted TCR-T cell therapy. The grant includes access to Wilson Wolf's G-Rex® bioreactors and Bio-Techne's new ProPak™ GMP Cytokines, designed to streamline reagent preparation and reduce costs in GMP manufacturing.

ImmunoScape plans to use the grant for pre-clinical process development, technology transfer to their CDMO partner, and generating data for an FDA IND submission planned for 2026. The G-Rex Grant Program, a $20M initiative by ScaleReady, aims to advance cell and gene-modified cell therapy development and manufacturing.

Positive

• Bio-Techne's involvement in the G-Rex® Grant Program may lead to increased adoption of their ProPak™ GMP Cytokines
• Potential for increased revenue from the sale of ProPak™ GMP Cytokines to grant recipients and other cell therapy companies
• Enhanced market positioning in the cell and gene therapy manufacturing sector

Negative

• None.

Insights

Biotechnology Analyst

ImmunoScape's $250,000 G-Rex® Grant marks a significant milestone in advancing their WT1-targeted TCR-T cell therapy. This grant will expedite the clinical readiness of their novel treatment, potentially accelerating the path to market. The incorporation of Wilson Wolf's closed-system G-Rex® bioreactors and early access to Bio-Techne's ProPak™ GMP Cytokines could lead to substantial cost savings and improved manufacturing efficiency.

The planned technology transfer to a CDMO partner for IND-enabling studies signals a strategic move towards commercialization. With the FDA submission targeted for 2026, ImmunoScape is positioning itself as a serious contender in the competitive TCR-T therapy landscape. This grant not only provides financial support but also offers valuable industry partnerships, potentially enhancing ImmunoScape's market position and attracting future investor interest.

Financial Analyst

The G-Rex® Grant Program, a $20 million initiative by ScaleReady, represents a strategic investment in the cell and gene therapy sector. For ImmunoScape, this $250,000 grant is a significant financial boost, potentially reducing R&D costs and accelerating time-to-market. This could lead to earlier revenue generation and improved ROI for investors.

The collaboration with established players like Bio-Techne (NASDAQ: TECH) adds credibility and could positively impact ImmunoScape's valuation. The promised cost savings from ProPak™ GMP Cytokines could improve future profit margins. While the 2026 FDA submission target seems distant, it provides a clear timeline for potential value inflection points. Investors should monitor ImmunoScape's progress, as successful development could lead to lucrative partnership opportunities or acquisition interest from larger biotech firms.

ST. PAUL, Minn., Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex^® Grant.  ImmunoScape's $250,000 G-Rex^® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell therapy.

"We are thankful for ScaleReady's G-Rex Grant Program and are grateful to receive an award that will substantially defray the time and cost of bringing our novel therapy into the clinic," said Dr. Tania Ribeiro, Senior Director and Head of CMC.

"We are proud to award ImmunoScape a G-Rex Grant to facilitate the clinical readiness of their novel TCR-T cell therapy.  Expediting the pathway to generating meaningful clinical data that their investors need to see is a primary objective of the G-Rex Grant Program. We are happy to see more private sector groups like ImmunoScape leveraging this unique program." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex^®.

As part of the G-Rex^® Grant, ImmunoScape plans to complete their pre-clinical process development including the incorporation of Wilson Wolf's fully closed-system G-Rex® bioreactors. ImmunoScape will also get early access to a new line of GMP cytokines from Bio-Techne that are tailor-made for use with G-Rex.  These new offerings, called ProPak™ GMP Cytokines, are designed to streamline reagent preparation and administration in a GMP manufacturing setting.  The new products will help companies like ImmunoScape save thousands of dollars per manufacturing run, while simplifying and streamlining processes for reduced variability.

Additionally, ImmunoScape's G-Rex Grant will help facilitate the technology transfer of their G-Rex centric manufacturing process to their contract development and manufacturing organization (CDMO) partner.  The G-Rex Grant will support training runs and engineering runs that will be used to generate the manufacturing batch records for an IND data package submission to the FDA, slated to occur in 2026.

ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and gene-modified cell therapy (CGT) development and manufacturing by awarding individual Grant Awards worth up to $300,000.  G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more.

About ImmunoScape
ImmunoScape is a biotechnology company developing next-generation TCR-T cell therapies for the treatment of solid tumors. By leveraging Deep Immunomics and AI-driven insights, ImmunoScape is focused on identifying TCRs with superior therapeutic potential, selecting the best candidates for clinical development. With multiple programs in the discovery and preclinical stages, the company is performing IND-enabling studies and preparing for the lead program to enter into the clinic and exploring strategic partnerships that align with our mission to bring next-generation TCR-T therapies to more patients. For more information, please visit https://immunoscape.com/.

About ScaleReady 
ScaleReady provides the field of cell and gene-modfied cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.

The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 4 commercially approved CGT drugs.

CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.

For more information about the ScaleReady G-Rex^® Grant Program, please contact info@scaleready.com.

About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex® technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.

Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.

About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex^® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416

About CellReady LLC
CellReady is the world's first and only G-Rex^® centric contract development and manufacturing organization (CDMO) specializing in G-Rex® based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies.

CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-immunoscape-302250120.html

SOURCE Bio-Techne Corporation

FAQ

What is the value of the G-Rex® Grant awarded to ImmunoScape by ScaleReady and Bio-Techne (NASDAQ: TECH)?

ImmunoScape was awarded a $250,000 G-Rex® Grant by ScaleReady, in collaboration with Bio-Techne (NASDAQ: TECH) and other partners.

How will the G-Rex® Grant help ImmunoScape's TCR-T cell therapy development?

The grant will enable ImmunoScape to complete pre-clinical process development, incorporate G-Rex® bioreactors, access Bio-Techne's ProPak™ GMP Cytokines, and facilitate technology transfer to their CDMO partner for IND-enabling studies.

When does ImmunoScape plan to submit their IND data package to the FDA for their TCR-T cell therapy?

ImmunoScape plans to submit their IND data package to the FDA in 2026, using the manufacturing batch records generated with support from the G-Rex® Grant.

What are the benefits of Bio-Techne's (NASDAQ: TECH) new ProPak™ GMP Cytokines for cell therapy manufacturing?

Bio-Techne's ProPak™ GMP Cytokines are designed to streamline reagent preparation, simplify processes, reduce variability, and save thousands of dollars per manufacturing run in GMP settings.